EA202090693A1 - Новый ингибитор mek для лечения вирусных и бактериальных инфекций - Google Patents

Новый ингибитор mek для лечения вирусных и бактериальных инфекций

Info

Publication number
EA202090693A1
EA202090693A1 EA202090693A EA202090693A EA202090693A1 EA 202090693 A1 EA202090693 A1 EA 202090693A1 EA 202090693 A EA202090693 A EA 202090693A EA 202090693 A EA202090693 A EA 202090693A EA 202090693 A1 EA202090693 A1 EA 202090693A1
Authority
EA
Eurasian Patent Office
Prior art keywords
viral
treatment
bacterial infections
mek inhibitor
infection
Prior art date
Application number
EA202090693A
Other languages
English (en)
Russian (ru)
Inventor
Штефан Людвиг
Оливер Планц
Original Assignee
Атрива Терапьютикс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Атрива Терапьютикс Гмбх filed Critical Атрива Терапьютикс Гмбх
Publication of EA202090693A1 publication Critical patent/EA202090693A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA202090693A 2017-10-17 2018-10-17 Новый ингибитор mek для лечения вирусных и бактериальных инфекций EA202090693A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU100487 2017-10-17
PCT/EP2018/078335 WO2019076947A1 (en) 2017-10-17 2018-10-17 NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
EA202090693A1 true EA202090693A1 (ru) 2020-10-19

Family

ID=60484427

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090693A EA202090693A1 (ru) 2017-10-17 2018-10-17 Новый ингибитор mek для лечения вирусных и бактериальных инфекций

Country Status (21)

Country Link
US (2) US11903917B2 (enExample)
EP (2) EP3973960B1 (enExample)
JP (3) JP7227967B2 (enExample)
KR (1) KR102848960B1 (enExample)
CN (2) CN118141795A (enExample)
AU (2) AU2018351475A1 (enExample)
BR (1) BR112020007442A2 (enExample)
CA (1) CA3078424A1 (enExample)
CY (1) CY1124507T1 (enExample)
DK (1) DK3697405T3 (enExample)
EA (1) EA202090693A1 (enExample)
ES (2) ES2883639T3 (enExample)
HR (1) HRP20211252T1 (enExample)
HU (1) HUE055738T2 (enExample)
LT (1) LT3697405T (enExample)
MX (2) MX2020003473A (enExample)
PL (1) PL3697405T3 (enExample)
PT (1) PT3697405T (enExample)
SI (1) SI3697405T1 (enExample)
WO (1) WO2019076947A1 (enExample)
ZA (1) ZA202002069B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2883639T3 (es) * 2017-10-17 2021-12-09 Atriva Therapeutics Gmbh Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
KR20220074869A (ko) 2019-08-27 2022-06-03 아트리바 테라퓨틱스 게엠베하 Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합
KR20220079573A (ko) * 2019-10-08 2022-06-13 아트리바 테라퓨틱스 게엠베하 한타바이러스 감염의 치료를 위한 mek 억제제
ES2995196T3 (en) * 2020-05-20 2025-02-07 Atriva Therapeutics Gmbh Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
CN112957361B (zh) * 2021-03-24 2022-07-29 中国科学院武汉病毒研究所 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
EP1140067A1 (en) * 1999-01-07 2001-10-10 Warner-Lambert Company Antiviral method using mek inhibitors
AU5786000A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
EP1467968A1 (en) 2002-01-23 2004-10-20 Warner-Lambert Company LLC N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
JP2007055983A (ja) * 2005-08-26 2007-03-08 Tokyo Univ Of Science 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤
US20150141380A1 (en) * 2010-08-05 2015-05-21 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
EP2903649A1 (en) * 2012-10-08 2015-08-12 Westfälische Wilhelms-Universität Münster Mek inhibitors in the treatment of virus diseases
WO2015173788A1 (en) * 2014-05-16 2015-11-19 Westfaelische Wilhelms-Universitaet Muenster Novel anti-infective strategy against influenza virus and s. aureus coinfections
ES2883639T3 (es) 2017-10-17 2021-12-09 Atriva Therapeutics Gmbh Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas
KR20220079573A (ko) 2019-10-08 2022-06-13 아트리바 테라퓨틱스 게엠베하 한타바이러스 감염의 치료를 위한 mek 억제제
ES2995196T3 (en) 2020-05-20 2025-02-07 Atriva Therapeutics Gmbh Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm

Also Published As

Publication number Publication date
US20200289445A1 (en) 2020-09-17
CY1124507T1 (el) 2022-07-22
SI3697405T1 (sl) 2021-11-30
US20240245637A1 (en) 2024-07-25
MX2020003473A (es) 2020-10-01
HUE055738T2 (hu) 2021-12-28
HRP20211252T1 (hr) 2021-11-12
JP7618276B2 (ja) 2025-01-21
JP7227967B2 (ja) 2023-02-22
PL3697405T3 (pl) 2021-12-13
CN111479566B (zh) 2024-05-07
PT3697405T (pt) 2021-08-27
JP2023058631A (ja) 2023-04-25
EP3973960C0 (en) 2025-09-03
ES2883639T3 (es) 2021-12-09
EP3697405A1 (en) 2020-08-26
EP3973960B1 (en) 2025-09-03
JP2020537659A (ja) 2020-12-24
CN118141795A (zh) 2024-06-07
CA3078424A1 (en) 2019-04-25
AU2018351475A1 (en) 2020-04-30
DK3697405T3 (da) 2021-08-23
EP3697405B1 (en) 2021-07-14
KR102848960B1 (ko) 2025-08-21
ES3041322T3 (en) 2025-11-11
BR112020007442A2 (pt) 2020-10-27
US11903917B2 (en) 2024-02-20
ZA202002069B (en) 2021-10-27
LT3697405T (lt) 2021-10-25
KR20200072499A (ko) 2020-06-22
EP3973960A1 (en) 2022-03-30
JP2025031917A (ja) 2025-03-07
WO2019076947A1 (en) 2019-04-25
AU2024205853A1 (en) 2024-09-05
MX2022016066A (es) 2023-02-02
CN111479566A (zh) 2020-07-31

Similar Documents

Publication Publication Date Title
EA202090693A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
EA201692303A1 (ru) Новая противоинфекционная стратегия против коинфекций, вызванных вирусом гриппа и s.aureus
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PH12022550033A1 (en) Compounds useful to treat influenza virus infections
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
PH12017500207B1 (en) Indoles for use in influenza virus infection
EA201691440A1 (ru) Производные азепана и способы лечения инфекций гепатита в
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа
EA201891975A1 (ru) Тиазолидные соединения для лечения вирусных инфекций
MX380393B (es) Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas.
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
EA202192454A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
TR201722950A2 (tr) Koah tedavisinde yeni farmasötik bileşimler.
PH12017501943A1 (en) Influenza virus neutralizing peptidomimetic compounds
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.